Citations to this article

Targeted enhancement of the biological activity of the antineoplastic agent, neocarzinostatin. Studies in murine neuroblastoma cells.
N F Schor
N F Schor
Published March 1, 1992
Citation Information: J Clin Invest. 1992;89(3):774-781. https://doi.org/10.1172/JCI115655.
View: Text | PDF
Research Article

Targeted enhancement of the biological activity of the antineoplastic agent, neocarzinostatin. Studies in murine neuroblastoma cells.

Abstract

The development of chemotherapeutic approaches to cancer has been hampered by the toxicity of proposed agents for normal rapidly dividing cells. By using neocarzinostatin, a "pro-drug" which is activated by reduction by thiol compounds, adjunctively with 6-mercaptodopamine, a thiol-containing dopamine analogue, we have been able to enhance neocarzinostatin toxicity for cells of the neural crest tumor neuroblastoma. Thiol compounds that are not neurotransmitter analogues do not act synergistically with neocarzinostatin in this system. Since most normal rapidly dividing cells do not have surface dopamine receptors, we propose this approach for the selective targeting of toxicity for neuroblastoma cells. We further introduce cell-selective activation of prodrugs as a new chemotherapeutic strategy which demands further development.

Authors

N F Schor

×

Total citations by year

Year: 2024 2016 2009 2008 2005 2002 2001 2000 1999 1997 1995 1994 1993 Total
Citations: 1 1 2 1 1 1 1 1 1 1 1 1 1 14
Citation information

Citations to this article (14)

Title and authors Publication Year
The Tangential Dialogue Between Science and Medicine: A Case in Point.
Schor NF 		Pediatric Neurology 2024
The “neuro” of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder: The “Neuro” of Neuroblastoma
N Ratner, GM Brodeur, RC Dale, NF Schor 		Annals of Neurology 2016
Frontiers in Neuroscience
K Panickar, S Bhathena 		Fat Detection 2009
New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence
NF Schor 		Pharmacology & Therapeutics 2009
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy
D Rogers, KD Nylander, Z Mi, T Hu, NF Schor 		Cancer Chemotherapy and Pharmacology 2008
Bcl-2-mediated potentiation of neocarzinostatin-induced apoptosis: requirement for caspase-3, sulfhydryl groups, and cleavable Bcl-2
Z Mi, B Hong, ZK Mirnics, YY Tyurina, VE Kagan, Y Liang, NF Schor 		Cancer Chemotherapy and Pharmacology 2005
Role of Caspase 3-Dependent Bcl-2 Cleavage in Potentiation of Apoptosis by Bcl-2
Y Liang, KD Nylander, C Yan, NF Schor 		Molecular pharmacology 2002
Apoptosis in the absence of caspase 3
Y Liang, C Yan, NF Schor 		Oncogene 2001
Cell line dependence of Bcl-2-induced alteration of glutathione handling
NF Schor, CM Rudin, AR Hartman, CB Thompson, YY Tyurina, VE Kagan 		Oncogene 2000
Neuroblastoma as a neurobiological disease
N F Schor 		Journal of Neuro-Oncology 1999
Cancer Therapeutics
BA Teicher 		1997
G-protein expression during enediyne-induced neurite outgrowth in neuroblastoma
NF Schor, KD Nylander, T Constantine, MC Schwartz 		Brain Research 1995
Effects of neocarzinostatin upon the development of tumors from murine neuroblastoma cells
P Will, KA Guger, NF Schor 		Cancer Chemotherapy and Pharmacology 1994
Prevention of neocarzinostatin-induced cell death and morphologic change in SK-N-SH human neuroblastoma cells by continuous exposure to nerve growth factor
M Falcione, KD Milligan, MC Schwartz, NF Schor 		Biochemical Pharmacology 1993

Advertisement